Question 1

Has Samuel Cytryn, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $17,799 in general payments to Samuel Cytryn, MD across 13 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Samuel Cytryn, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Samuel Cytryn, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
AstraZeneca	3	$6,680
E.r. Squibb & Sons, L.L.C.	2	$4,070
Fosun Pharma USA Inc.	2	$2,587
Amgen	2	$2,023
Astellas Pharma US Inc	2	$1,279
Gilead	2	$1,160

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	17	$18,500
Prochlorperazine Maleate	54	$1,547
Ondansetron Hcl	56	$1,525
Fentanyl	14	$509
Dexamethasone	28	$275
Oxycodone Hcl	17	$272
Olanzapine	14	$189
Pantoprazole Sodium	13	$85

Samuel Cytryn, MD

Payments from drug & device makers

Who reported the general payments

What the payments were tied to

How this compares

Medicare billing

Most prescribed under Part D

Other internal medicine in New York